Gain Therapeutics Inc. has announced additional biomarker and clinical data from its Phase 1b clinical study of GT-02287 in individuals with Parkinson's disease, with or without a GBA1 mutation. The results, which support the disease-modifying potential of GT-02287, show a decrease in GluSph levels and stabilization or improvement in MDS-UPDRS scores after 90 days of dosing. Anecdotal improvements were also observed in balance, gait, and sense of smell. These findings were presented during a virtual KOL event on January 6, 2026. The company reported that 15 patients were included in the final analysis, with an average improvement of 2.20 points in the sum of MDS-UPDRS Part II and Part III scores. Gain Therapeutics plans to assess longer-term outcomes in the ongoing extension phase of the study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620564-en) on January 06, 2026, and is solely responsible for the information contained therein.